Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

Led by new CEO Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals has a stated ambition to transition the RNA interference therapeutics trailblazer to a top 5 biotech – measured by market capitalization – within the next five years.

Valneva said on January 19 that preliminary studies showed three doses of the French biotech firm’s inactivated COVID-19 vaccine candidate neutralized the Omicron variant of the disease.

Prellis Biologics entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing the Bay Area biotechnology company’s first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO).

NRx Pharmaceuticals filed a counter lawsuit against Relief Therapeutics, the company it initially partnered with to develop the experimental COVID-19 treatment aviptadil, which was submitted to the U.S. Food and Drug Administration for Emergency Use Authorization.

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region’s principal trade association for small to medium-sized companies in the pharmaceutical, biotech and medtech industries.

Japan’s Takeda Pharmaceutical announced deals with two biotech companies, Seattle-based Immusoft and San Diego’s Poseida Therapeutics.

Honeycomb Health, a project being created out of Greater Than One’s nonprofit subsidiary GTO Greater Good, was named a finalist in the Top 8 That Innovate. The Top 8 were selected by a panel of pharmaceutical and biotech companies that are members of the Diversity Alliance for Science.

Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.

Emergent BioSolutions signed a five-year agreement with Providence Therapeutics to develop and manufacture the Canadian biotechnology company’s Covid-19 vaccine candidate for about $90 million.